Myc在小细胞肺癌中的研究进展

Research progress of Myc in small cell lung cancer

小细胞肺癌(small cell lung cancer,SCLC)是一种侵袭性恶性肿瘤,占所有肺癌诊断的14%。尽管经过了数十年的积极研究,SCLC的治疗方案仍然有限。迄今为止,SCLC还没有批准的靶向药物,因此需要进一步研究SCLC的靶向治疗。作为SCLC中常见的一种遗传畸变,Myc家族成员显得尤为突出。过去几年的研究表明,直接靶向Myc显得寸步难行,故人们广泛研究了间接抑制Myc活性的方法。在这篇综述中,我们描述了Myc的概念和它在SCLC中的作用,回顾了SCLC现有的治疗方法,总结了Myc抑制剂在SCLC中的最新研究进展。

Small cell lung cancer(SCLC) is an aggressive cancer that accounts for 14% of all lung cancer diagnoses.Despite decades of active research,SCLC’s treatment options are still limited.So far,SCLC has not approved targeted drugs,so further research on SCLC targeted therapies is needed.As a common genetic aberrations in SCLC.Myc family members are particularly prominent.Studies in the past few years have shown that direct targeting of Myc appears to be difficult,so people have extensively studied ways to indirectly inhibit Myc activity.In this review,we describe the concept of Myc and its role in SCLC.We review SCLC’s existing treatments and summarize recent advances in Myc inhibitors in SCLC.